Immunoglobulin A

Oragenics Issues Letter to Shareholders

Retrieved on: 
Tuesday, May 17, 2022 - 12:30pm

I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress.

Key Points: 
  • I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress.
  • In previous letters I affirmed the strategic direction Oragenics is taking and discussed our commitment to the speedy yet prudent execution of our development work.
  • Through this letter I aim to provide clarity on the opportunity, rationale and pathway toward human clinical testing.
  • On behalf of the Oragenics Board of Directors, I thank you for your continued support and look forward to keeping you apprised of our ongoing progress.

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022 - 12:30pm

Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.

Key Points: 
  • Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Enrollment in the Phase 2b ORIGIN clinical trial of atacicept remains on track, topline data expected in the fourth quarter 2022.
  • Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

Retrieved on: 
Monday, May 16, 2022 - 12:00pm

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Key Points: 
  • SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
  • For decades people living with IgA nephropathy have had limited treatment options while facing a progression toward end-stage kidney disease.
  • If approved, sparsentan would be the first FDA-approved non-immunosuppressive treatment option for IgA nephropathy, and we aspire to ultimately position sparsentan as a new standard of care, said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
  • Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN and FSGS in the U.S. and Europe.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, May 12, 2022 - 9:20pm

The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.

Key Points: 
  • The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
  • The Company granted the stock options as a material inducement to this employee for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases.

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022 - 9:00pm

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
  • In March 2022, Chinook presented an overview of the phase 2 AFFINITY clinical trial at the 4th Annual Chronic Kidney Disease (CKD) Drug Development Summit.
  • In February 2022, Chinook delivered an encore trials-in-progress presentations on the phase 3 ALIGN and phase 2 AFFINITY clinical trials at the ISN World Congress of Nephrology 2022.
  • In March 2022, Chinook presented a detailed overview of the BION-1301 program at the 4th Annual CKD Drug Development Summit.

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022 - 10:46pm

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

Key Points: 
  • Results from Vaxarts Phase IB trial of its norovirus vaccine candidate in elderly subjects are expected in the second quarter of 2022.
  • The Companyreported a net loss of$25.1 millionfor the first quarter of 2022, compared to$16.0 million for the first quarter of 2021.
  • Research and development expenses were$18.2 millionfor the first quarter of 2022, compared to$10.1 million for the first quarter of 2021.
  • General and administrative expenses were$6.7 millionfor the first quarter of 2022, compared to$5.9 million the first quarter of 2021.

Vera Therapeutics to Present at Upcoming Conferences in May 2022

Retrieved on: 
Thursday, May 5, 2022 - 9:05pm

A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.

Key Points: 
  • A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.
  • Veras mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

Travere Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022 - 9:01pm

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Key Points: 
  • SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.
  • Total other expense, net, for the first quarter of 2022 was $9.8 million, compared to $6.0 million for the same period in 2021.
  • ET to discuss company updates as well as first quarter 2022 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022 - 12:30pm

Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR.

Key Points: 
  • Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR.
  • Selecta continues work toward identifying suitable target indications and accelerating the development of ImmTOR-IL to the clinic.
  • Selecta expects initiation of the Phase 1 clinical trial of SEL-302 in the second half of 2022.
  • Selecta management will host a conference call at 8:30 AM ET today to provide a corporate update and review the companys first quarter 2022 financial results.